XML 36 R26.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Collaborative Arrangements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Collaborative Arrangements [Abstract] |
Collaboration Arrangements | Summarized financial information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Alliance revenue - Lynparza | $ | 284 |  |  | $ | 246 |  |  | $ | 825 |  |  | $ | 721 |
Alliance revenue - Koselugo | 10 |  |  | 6 |  |  | 43 |  |  | 20 |
Total alliance revenue | $ | 294 |  |  | $ | 252 |  |  | $ | 868 |  |  | $ | 741 |
Cost of sales (1) | 64 |  |  | 42 |  |  | 425 |  |  | 125 |
Selling, general and administrative | 45 |  |  | 44 |  |  | 135 |  |  | 127 |
Research and development | 28 |  |  | 27 |  |  | 79 |  |  | 87 |
($ in millions) |  |  |  |  | September 30, 2022 |  | December 31, 2021
Receivables from AstraZeneca included in Other current assets |  |  |  |  | $ | 290 |  |  | $ | 271 |
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2) |  |  |  |  | 12 |  |  | 415 |
Payables to AstraZeneca included in Other Noncurrent Liabilities (2) |  |  |  |  | 600 |  |  | — |
(1) Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250 million of cumulative amortization catch-up expense as noted above. (2) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Alliance revenue - Lenvima | $ | 202 |  |  | $ | 188 |  |  | $ | 660 |  |  | $ | 498 |
Cost of sales (1) | 53 |  |  | 49 |  |  | 159 |  |  | 143 |
Selling, general and administrative | 42 |  |  | 34 |  |  | 115 |  |  | 88 |
Research and development | 24 |  |  | 43 |  |  | 128 |  |  | 165 |
($ in millions) |  |  |  |  | September 30, 2022 |  | December 31, 2021
Receivables from Eisai included in Other current assets |  |  |  |  | $ | 202 |  |  | $ | 200 |
Payables to Eisai included in Accrued and other current liabilities (2) |  |  |  |  | 1 |  |  | 625 |
(1) Represents amortization of capitalized milestone payments. (2) Amount as of December 31, 2021 includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Alliance revenue - Adempas/Verquvo | $ | 88 |  |  | $ | 100 |  |  | $ | 258 |  |  | $ | 248 |
Net sales of Adempas recorded by Merck | 57 |  |  | 59 |  |  | 181 |  |  | 188 |
Net sales of Verquvo recorded by Merck | 6 |  |  | 2 |  |  | 15 |  |  | 3 |
Total sales | $ | 151 |  |  | $ | 161 |  |  | $ | 454 |  |  | $ | 439 |
Cost of sales (1) | 55 |  |  | 53 |  |  | 158 |  |  | 328 |
Selling, general and administrative | 42 |  |  | 31 |  |  | 107 |  |  | 84 |
Research and development | 18 |  |  | 16 |  |  | 52 |  |  | 36 |
($ in millions) |  |  |  |  | September 30, 2022 |  | December 31, 2021
Receivables from Bayer included in Other current assets |  |  |  |  | $ | 144 |  |  | $ | 114 |
Payables to Bayer included in Accrued and other current liabilities (2) |  |  |  |  | 75 |  |  | 472 |
(1) Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. (2) Amount as of December 31, 2021 includes accrued milestone payment. Summarized financial information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Lagevrio sales | $ | 436 |  |  | $ | — |  |  | $ | 4,859 |  |  | $ | — |
Cost of sales (1) | 234 |  |  | 4 |  |  | 2,580 |  |  | 56 |
Selling, general and administrative | 41 |  |  | 6 |  |  | 105 |  |  | 13 |
Research and development | 8 |  |  | 58 |  |  | 29 |  |  | 167 |
($ in millions) |  |  |  |  | September 30, 2022 |  | December 31, 2021
Payables to Ridgeback included in Accrued and other current liabilities (2) |  |  |  |  | $ | 193 |  |  | $ | 283 |
(1) Includes royalty expense and amortization of capitalized milestone payments. (2) Includes accrued royalty and milestone payments.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration